文献速递前列腺增生与排尿功能障碍

水蒸气热疗与多沙唑嗪、非那雄胺及联合治疗对良性前列腺增生继发下尿路症状的五年结局比较:来自MTOPS试验的队列数据

Five-Year Outcomes of Water Vapor Therapy vs Doxazosin, Finasteride, and Combination Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Cohort Data From the Medical Therapy of Prostatic Symptoms Trial.
PubMed 文献 · Urology · 2025-07-17

本研究将Rezūm水蒸气热疗随机对照试验治疗组与MTOPS试验中接受多沙唑嗪、非那雄胺、联合治疗或安慰剂且符合Rezūm试验标准的受试者进行比较,采用倾向评分逆概率加权调整混杂因素,随访5年。结果显示水蒸气热疗5年临床进展率最低为4.6%,症状改善与非那雄胺和联合治疗相似,但优于多沙唑嗪和安慰剂;客观指标改善随时间变化,峰值尿流率仅前3年有获益,残余尿无优于安慰剂。

要点

  • 水蒸气热疗5年临床进展率为4.6%,低于药物组。
  • 症状改善与非那雄胺和联合治疗相似,优于多沙唑嗪和安慰剂。
  • 峰值尿流率获益仅维持3年,残余尿无优于安慰剂。

核心结论

  • 水蒸气热疗患者5年临床进展率较低,对合适患者可能优于药物治疗。
  • 单次Rezūm治疗的症状改善初期优于每日长期药物,但优势随时间减弱。

研究设计与样本

  • 将Rezūm系统随机对照试验治疗组与MTOPS试验中接受多沙唑嗪、非那雄胺、联合治疗或安慰剂的受试者进行比较。
  • 仅纳入符合Rezūm试验标准的MTOPS受试者(前列腺体积30-80 cc,IPSS≥13)。
  • 采用倾向评分逆概率加权调整潜在混杂变量,比较5年主观、客观及临床进展结局。

主要发现

  • 水蒸气热疗后症状评分从基线持续改善至5年(ΔIPSS:3个月-11.1,5年-9.5)。
  • 5年时水蒸气热疗临床进展率最低为4.6%。
  • Rezūm后客观结局随访期间变化较大,峰值尿流率仅前3年有获益,残余尿无优于安慰剂。

关键数值与推荐

  • MTOPS受试者纳入标准:前列腺体积30-80 cc,IPSS≥13。
  • 水蒸气热疗5年临床进展率为4.6%。

临床怎么用

  • 对于符合标准(前列腺体积30-80 cc,IPSS≥13)的BPH继发LUTS患者,水蒸气热疗可考虑作为药物治疗的替代选择。
  • 需告知患者单次Rezūm治疗的症状改善优势随时间减弱,客观指标获益有限。

局限性

  • 研究为跨试验比较,非直接随机对照,尽管采用倾向评分加权仍可能存在残余混杂。
  • Rezūm试验与MTOPS试验在设计和人群上存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare 5-year clinical and subjective treatment outcomes of water vapor thermal therapy to Medical Therapy of Prostatic Symptoms (MTOPS) trial cohorts receiving doxazosin, finasteride, or combination therapy. METHODS: MTOPS subjects who received doxazosin, finasteride, combination therapy, or placebo (ClinicalTrials.gov NCT00021814) were compared to the treatment arm of a randomized controlled trial of thermal therapy using the Rezūm System (NCT01912339). Only MTOPS subjects who met criteria for the Rezūm trial were included (prostate volume 30-80 cc, International Prostate Symptom Score [IPSS] ≥ 13). Inverse probability weighting by the propensity score was used to adjust for potential confounding variables. Subjective, objective, and clinical progression outcomes were compared over 5-year. RESULTS: Symptom scores improved from baseline after thermal therapy throughout the study (∆ IPSS = -11.1 at 3months to -9.5 at 5years). By 5 years, thermal therapy had the lowest rate of clinical progression at 4.6% while thermal therapy symptom improvement was similar to finasteride (P = .10) and combination therapy (0.77) but remained superior to doxazosin (P = .004) and placebo groups (P = .035). Objective outcomes after Rezūm were more variable throughout follow-up, with peak flow showing benefit through year 3 only, and no benefit over placebo with respect to postvoid residual. CONCLUSION: Water vapor thermal therapy patients experienced lower rates of clinical progression at 5-year post-treatment and thus may represent a benefit compared to pharmaceutical therapy for appropriately selected patients. Additionally, a single Rezūm treatment produces symptom score improvements that are initially superior to daily long-term medication, however, this advantage wanes over time.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Long B, Cheema A, Copelan O, et al. Five-Year Outcomes of Water Vapor Therapy vs Doxazosin, Finasteride, and Combination Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Cohort Data From the Medical Therapy of Prostatic Symptoms Trial. Urology. 2025. PMID: 40683564. doi:10.1016/j.urology.2025.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。